|Follow us :|
Luai Al Bakour
El Temamy Pharmacy
Akoni Hijyen Teknolojileri Sanayi ve Dış Ticaret LTD. ŞTİ
Britton Chance Center for Biomedical Photonics
Arabian Trade Center - ATC
Medical Facility (32206):
Legality International. (Pvt.) Ltd.
MainYou must sign in to use this servcie
Feedback - Please use the form below to send your query or comment
You must sign in to use this servcie
To aid in the treatment of rheumatism. this medicine should only be administered when other NSAIDs have not produced satisfactory results and only against acute outbreaks of the following conditions: * Ankylosing spondylitis. * Gout. * Rheumatoid arthritis. * Osteoarthritis.
this medicine is contraindicated in patients with hypersensitivity to pyrazolones phenylbutazone and other derivatives, with obvious gastric ulcer or a history of it, with symptoms or history of inflammatory bowel disease with or without ulceration, blood dyscrasias, or history of them, bleeding diathesis ( thrombocytopenia, coagulation disorders), severe heart failure, liver or kidney disease, severe hypertension, thyroid disease, Sjogren’s syndrome. this medicine is also contraindicated in asthmatic patients in which the making of salicylic acid or other drugs with inhibitory activity of prostaglandin synthetase triggers asthma attacks, urticaria, acute rhinitis or other manifestations of hypersensitivity.
Gastrointestinal tract: Common: nausea, gas-tritis. Occasional: gastrointestinal upset, heartburn, epigastric pain, peptic ulcer, diarrhea. Rare: vomiting, gastrointestinal bleeding (hematemesis and / or melena), bleeding or perforation of peptic ulcers. In isolated cases: pancreatitis, esophagitis, esophageal ulcer, benign esophageal narrowing, exacerbation of inflammatory bowel disease, including Crohn’s disease with bleeding, ulceration or perforation, small bowel obstruction, constipation.
this medicine can increase the activity, the duration of the effect and toxicity of oral anticoagulants (risk of bleeding), the oral agents (risk of serious hypoglycemia) of insulin, phenytoin, sodium valproate, lithium, methotrexate and sulfonamides. this medicine can induce hepatic microsomal metabolism of dicumarol, digitoxin, hexobarbital and cortisone. Inducers of hepatic microsomal enzymes, eg barbiturates, promethazine, chlorpheniramine, rifampicin and corticosteroids (prednisone) may shorten the average life of this medicine. Conversely, methylphenidate has been reported to prolong the lifetime of this medicine and increases the serum concentration of oxyphenbutazone. Concomitant administration of this medicine with other NSAIDs or corticosteroids increases the risk of causing serious gastrointestinal adverse reactions. Administered together, this medicine and misoprostol can induce adverse symptoms related to central nervous system such as dizziness, headache and transient diplopia. this medicine may potentiate the effects of alcohol on the central nervous system. Cholestyramine and antacids reduce this medicine enteral resorption. During concomitant administration of anabolic steroids (methandrostenolone) and this medicine, increases the plasma concentration of oxyphenbutazone.
It can occur at any time a serious gastrointestinal toxicity and bleeding, ulceration and perforation, with or without premonitory symptoms in patients treated with nonsteroidal antiinflammatory drugs. Although less common gastrointestinal symptoms such as dyspepsia, they usually occur at the beginning of therapy. Physicians should remain alert for ulcers and bleeding in patients treated with NSAIDs, even in the absence of previous symptoms in the gastrointestinal tract. If it shows any signs or symptoms suggesting gastrointestinal toxicity, were suspended immediately this medicine administration. If patients develop signs or symptoms suggestive of discretion sia of blood cells such as fever, stomatitis, sore throat or prolonged bleeding, discontinue the medication immediately this medicine and perform a complete blood analysis. Have been reported with severe liver this medicine reactions, including jaundice and hepatitis, as with other nonsteroidal anti-inflammatory drugs. If they persist the results of liver tests abnormal or worsen or develop clinical signs and symptoms of liver disease, discontinue drug administration. Like other drugs that inhibit the activity of prostaglandin synthetase, this medicine may precipitate acute asthma attacks in asthmatic patients. It is recommended not this medicine administered to patients under 12 years. The elderly may be at greater risk of adverse side effects with nonsteroidal anti-inflammatory drugs. Therefore, this medicine be used with caution in such patients. If you have to manage this medicine for over a week, will carry out regular tests of liver and kidney function and blood counts. If significant changes are manifested, will withdraw the drug. this medicine increases sodium retention. Therefore be used with caution in patients where fluid retention would aggravate an underlying condition such as heart or kidney disease. Patients with impaired renal function should be closely monitored. May precipitate overt renal failure due to inhibition of prostaglandin synthesis. In patients with stomatitis should be excluded granulocytopenia or aplastic anemia before initiating therapy with this medicine. Even if the blood count is normal, this medicine be used with caution in patients with stomatitis. Patients treated with this medicine avoid taking aspirin and other NSAIDs, since concomitant use of these drugs may increase the risk of serious gastrointestinal reactions. No action shall this medicine to patients undergoing oral anticoagulant therapy because of an increased risk of bleeding. Patients treated with oral agents should not receive this medicine about the possibility of occurrence of serious hypoglycemia.
SOLUTION FOR INJECTION
Dosage and AdministrationYou must sign in to use this servcie
Technical DescriptionYou must sign in to use this servcie
Dr. Hani Najjar
Dr. Talal Sabouni
Dr. Tahsin Martini
Dr . Dirar Abboud
Yaser Habrawi , F.R.C.S.Ed
Dr. Faisal Dibsi
Dr. Samer Al-Jneidy
Samir Moussa M.D.